Zubin Bhagwagar
Overview
Explore the profile of Zubin Bhagwagar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
2500
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Geisen C, Kjaer M, Fleck E, Skogen B, Armstrong R, Behrens F, et al.
J Thromb Haemost
. 2023 Jan;
21(4):838-849.
PMID: 36696185
Background: Fetal/neonatal alloimmune thrombocytopenia (FNAIT) is a rare and potentially life-threatening bleeding disorder of the fetus/newborn. Antibodies against human platelet antigen 1a (HPA-1a) are associated with the most frequent FNAIT...
2.
Kleykamp B, Dworkin R, Turk D, Bhagwagar Z, Cowan P, Eccleston C, et al.
Pain
. 2021 Sep;
163(6):1006-1018.
PMID: 34510135
Chronic pain clinical trials have historically assessed benefit and risk outcomes separately. However, a growing body of research suggests that a composite metric that accounts for benefit and risk in...
3.
Smith S, Dworkin R, Turk D, McDermott M, Eccleston C, Farrar J, et al.
Pain
. 2020 Jun;
161(11):2446-2461.
PMID: 32520773
Interpreting randomized clinical trials (RCTs) is crucial to making decisions regarding the use of analgesic treatments in clinical practice. In this article, we report on an Initiative on Methods, Measurement,...
4.
Baldassarri S, Park E, Finnema S, Planeta B, Nabulsi N, Najafzadeh S, et al.
Synapse
. 2020 Apr;
74(10):e22159.
PMID: 32324935
Serotonergic neurotransmission plays a key role in the pathophysiology and treatment of various neuropsychiatric diseases. The purpose of this study was to investigate changes in serotonergic neurotransmission after acute tryptophan...
5.
Young T, Srinivasan S, Vetter M, Sethuraman V, Bhagwagar Z, Zwirtes R, et al.
J Clin Pharmacol
. 2017 May;
57(9):1079-1087.
PMID: 28510323
A systematic review of the Bristol-Myers Squibb normal healthy volunteers (NHVs) database identified phase 1 trials that included NHVs administered placebo with the aim of characterizing normal inter- and intraindividual...
6.
Pittenger C, Adams Jr T, Gallezot J, Crowley M, Nabulsi N, James Ropchan , et al.
J Affect Disord
. 2016 Feb;
196:87-96.
PMID: 26919057
Obsessive-compulsive disorder (OCD) is characterized by impaired sensorimotor gating, as measured using prepulse inhibition (PPI). This effect may be related to abnormalities in the serotonin (5-HT) system. 5-HT1B agonists can...
7.
Bhagwagar Z, Torbeyns A, Hennicken D, Zheng M, Dunlop B, Mathew S, et al.
J Clin Psychopharmacol
. 2015 May;
35(4):454-9.
PMID: 25961781
Two phase 2B, randomized, double-blind studies assessed the efficacy and safety of fixed or flexible dose of triple monoamine uptake inhibitor BMS-820836 in patients with treatment-resistant depression to demonstrate whether...
8.
Zheng M, Burt D, Chan W, Hawthorne D, Gasior M, Bhagwagar Z, et al.
J Clin Pharmacol
. 2015 Apr;
55(10):1137-46.
PMID: 25904041
As BMS-820836 causes dose-dependent heart rate increases, QTcI, QTcF, QTcB, and QT beat-to-beat methods were compared in this thorough QT study in healthy subjects. Two parallel groups of subjects (n ...
9.
Saricicek A, Chen J, Planeta B, Ruf B, Subramanyam K, Maloney K, et al.
Eur J Nucl Med Mol Imaging
. 2014 Nov;
42(3):468-77.
PMID: 25427881
Purpose: [(11)C]P943 is a novel, highly selective 5-HT1B PET radioligand. The aim of this study was to determine the test-retest reliability of [(11)C]P943 using two different modeling methods and to...
10.
Zheng M, Appel L, Luo F, Lane R, Burt D, Risinger R, et al.
Psychopharmacology (Berl)
. 2014 Aug;
232(3):529-40.
PMID: 25116481
Rationale: BMS-820836 is a novel antidepressant that selectively inhibits the reuptake of serotonin, norepinephrine, and dopamine. Objective: This Phase I study assessed safety, tolerability, and pharmacokinetics of multiple daily doses...